Table 6.
Other drugs with significant protective associations (limited to FDR < 0.05) within time windows of 6, 12, and 24 months.
| Window | Model | ATC Code | OR | conf.low | conf.high | p | FDR.BH | Full Name |
|---|---|---|---|---|---|---|---|---|
| 0.5 year | F | A02BC | 0.72 | 0.67 | 0.79 | 1.05 × 10−13 | 2.18 × 10−11 | Proton pump inhibitors |
| 0.5 year | G | A02BC | 0.70 | 0.61 | 0.81 | 1.06 × 10−6 | 2.08 × 10−5 | Proton pump inhibitors |
| 1 year | A | A02BC | 0.77 | 0.65 | 0.91 | 2.37 × 10−3 | 1.78 × 10−2 | Proton pump inhibitors |
| 1 year | F | A02BC | 0.77 | 0.71 | 0.83 | 2.01 × 10−11 | 2.38 × 10−9 | Proton pump inhibitors |
| 1 year | G | A02BC | 0.66 | 0.58 | 0.76 | 1.56 × 10−9 | 7.80 × 10−8 | Proton pump inhibitors |
| 2 years | A | A02BC | 0.77 | 0.66 | 0.90 | 1.05 × 10−3 | 1.80 × 10−2 | Proton pump inhibitors |
| 2 years | F | A02BC | 0.80 | 0.74 | 0.86 | 2.94 × 10−9 | 2.55 × 10−7 | Proton pump inhibitors |
| 2 years | G | A02BC | 0.68 | 0.59 | 0.77 | 1.81 × 10−9 | 9.96 × 10−8 | Proton pump inhibitors |
| 2 years | F | A03FA | 0.51 | 0.37 | 0.70 | 3.67 × 10−5 | 1.19 × 10−3 | Propulsives |
| 1 year | F | A09AA | 0.24 | 0.09 | 0.64 | 4.19 × 10−3 | 3.97 × 10−2 | Enzyme preparations |
| 2 years | F | A09AA | 0.23 | 0.09 | 0.60 | 2.81 × 10−3 | 3.48 × 10−2 | Enzyme preparations |
| 0.5 year | F | A12AX | 0.80 | 0.69 | 0.93 | 2.74 × 10−3 | 3.49 × 10−2 | Calcium, combinations with vitamin D and/or other drugs |
| 1 year | F | A12AX | 0.83 | 0.72 | 0.94 | 4.36 × 10−3 | 3.97 × 10−2 | Calcium, combinations with vitamin D and/or other drugs |
| 1 year | F | B03AA | 0.74 | 0.60 | 0.91 | 4.00 × 10−3 | 3.97 × 10−2 | Iron bivalent, oral preparations |
| 2 years | F | C05AE | 0.33 | 0.16 | 0.69 | 3.18 × 10−3 | 3.59 × 10−2 | Muscle relaxants |
| 0.5 year | F | G03CA | 0.63 | 0.52 | 0.76 | 3.03 × 10−6 | 1.58 × 10−4 | Natural and semisynthetic estrogens, plain |
| 1 year | F | G03CA | 0.67 | 0.58 | 0.78 | 4.08 × 10−7 | 2.42 × 10−5 | Natural and semisynthetic estrogens, plain |
| 2 years | F | G03CA | 0.70 | 0.61 | 0.80 | 1.89 × 10−7 | 9.83 × 10−6 | Natural and semisynthetic estrogens, plain |
| 2 years | G | G03CA | 0.66 | 0.51 | 0.86 | 2.43 × 10−3 | 3.35 × 10−2 | Natural and semisynthetic estrogens, plain |
| 0.5 year | F | G04CB | 0.63 | 0.46 | 0.85 | 3.02 × 10−3 | 3.49 × 10−2 | Testosterone-5-alpha reductase inhibitors |
| 0.5 year | F | H03AA | 0.80 | 0.69 | 0.92 | 2.24 × 10−3 | 3.11 × 10−2 | Thyroid hormones |
| 0.5 year | G | H03AA | 0.66 | 0.51 | 0.86 | 2.10 × 10−3 | 1.96 × 10−2 | Thyroid hormones |
| 1 year | C | H03AA | 0.62 | 0.48 | 0.79 | 1.77 × 10−4 | 6.57 × 10−4 | Thyroid hormones |
| 1 year | E | H03AA | 0.80 | 0.71 | 0.92 | 9.47 × 10−4 | 4.23 × 10−3 | Thyroid hormones |
| 1 year | F | H03AA | 0.81 | 0.71 | 0.93 | 2.51 × 10−3 | 2.98 × 10−2 | Thyroid hormones |
| 1 year | G | H03AA | 0.64 | 0.49 | 0.82 | 5.53 × 10−4 | 6.50 × 10−3 | Thyroid hormones |
| 2 years | C | H03AA | 0.62 | 0.48 | 0.79 | 1.50 × 10−4 | 7.36 × 10−4 | Thyroid hormones |
| 2 years | E | H03AA | 0.80 | 0.70 | 0.91 | 5.94 × 10−4 | 2.81 × 10−3 | Thyroid hormones |
| 2 years | F | H03AA | 0.81 | 0.71 | 0.93 | 2.57 × 10−3 | 3.35 × 10−2 | Thyroid hormones |
| 2 years | G | H03AA | 0.64 | 0.50 | 0.83 | 6.06 × 10−4 | 9.52 × 10−3 | Thyroid hormones |
| 1 year | F | J01MA | 0.49 | 0.34 | 0.72 | 2.40 × 10−4 | 5.93 × 10−3 | Fluoroquinolones |
| 2 years | F | J01MA | 0.59 | 0.46 | 0.76 | 5.39 × 10−5 | 1.56 × 10−3 | Fluoroquinolones |
| 0.5 year | F | L02AE | 0.29 | 0.14 | 0.60 | 9.84 × 10−4 | 1.86 × 10−2 | Gonadotropin releasing hormone analogues |
| 1 year | F | L02AE | 0.41 | 0.23 | 0.72 | 2.02 × 10−3 | 2.62 × 10−2 | Gonadotropin releasing hormone analogues |
| 2 years | F | L02AE | 0.42 | 0.25 | 0.70 | 9.73 × 10−4 | 1.49 × 10−2 | Gonadotropin releasing hormone analogues |
| 0.5 year | F | M01AE | 0.68 | 0.56 | 0.82 | 4.61 × 10−5 | 1.37 × 10−3 | Propionic acid derivatives |
| 1 year | F | M01AE | 0.79 | 0.70 | 0.91 | 6.65 × 10−4 | 1.29 × 10−2 | Propionic acid derivatives |
| 0.5 year | F | N02AX | 0.56 | 0.41 | 0.76 | 1.88 × 10−4 | 4.33 × 10−3 | Other opioids |
| 1 year | F | N02AX | 0.63 | 0.49 | 0.80 | 1.63 × 10−4 | 4.84 × 10−3 | Other opioids |
| 2 years | F | N02AX | 0.68 | 0.56 | 0.83 | 1.14 × 10−4 | 2.29 × 10−3 | Other opioids |
| 0.5 year | F | N03AX | 0.68 | 0.58 | 0.81 | 1.72 × 10−5 | 5.96 × 10−4 | Other antiepileptics |
| 1 year | F | N03AX | 0.70 | 0.60 | 0.82 | 1.00 × 10−5 | 3.95 × 10−4 | Other antiepileptics |
| 2 years | F | N03AX | 0.73 | 0.64 | 0.84 | 7.15 × 10−6 | 3.10 × 10−4 | Other antiepileptics |
| 0.5 year | F | N06AA | 0.77 | 0.65 | 0.92 | 3.99 × 10−3 | 4.15 × 10−2 | Nonselective monoamine reuptake inhibitors |
| 1 year | F | N06AA | 0.79 | 0.68 | 0.92 | 1.98 × 10−3 | 2.62 × 10−2 | Nonselective monoamine reuptake inhibitors |
| 2 years | F | N06AA | 0.79 | 0.70 | 0.90 | 2.67 × 10−4 | 4.96 × 10−3 | Nonselective monoamine reuptake inhibitors |
| 1 year | A | R03BA | 0.48 | 0.31 | 0.73 | 7.44 × 10−4 | 7.44 × 10−3 | Glucocorticoids |
| 2 years | A | R03BA | 0.55 | 0.38 | 0.81 | 2.44 × 10−3 | 3.36 × 10−2 | Glucocorticoids |
| 0.5 year | F | R05DA | 0.69 | 0.55 | 0.87 | 1.46 × 10−3 | 2.33 × 10−2 | Opium alkaloids and derivatives |
| 1 year | F | R05DA | 0.74 | 0.62 | 0.88 | 5.47 × 10−4 | 1.18 × 10−2 | Opium alkaloids and derivatives |
| 2 years | F | R05DA | 0.80 | 0.70 | 0.91 | 7.02 × 10−4 | 1.22 × 10−2 | Opium alkaloids and derivatives |
For space limits, only results with FDR < 0.05 are shown. Please refer to Tables S3 and S6 for full results. Ophthalmological and other topical agents are not listed in the above table.